Genocea Biosciences Inc. (GNCA) 18.28 $GNCA
Genocea Reports First Quarter 2014 Financial Results
Business Wire - Tue May 06, 7:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported its financial results for the first quarter ended March 31, 2014.
Genocea to Announce First Quarter 2014 Financial Results on May 6, 2014
Business Wire - Tue Apr 29, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on May 6, 2014 at 9:00 a.m. ET to discuss financial results for the quarter ended March 31, 2014. The presentation, hosted by Genocea president and chief executive officer Chip Clark and chief financial officer Jonathan Poole, will also provide an update on the company's recent progress and upcoming milestones.
Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles
M2 - Mon Apr 28, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zbrdd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Vical Incorporated - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Nutra Pharma Corporation - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - Spider Biotech S.r.l. - Kala Pharmaceuticals, Inc. - Coridon Pty Ltd - Sanofi Pasteur SA - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - amenamevir - tenofovir - RPI-78M - RPI-MN - HSV-2 Vaccine - CEL-1000 - HSV Vaccine - HSV-2 Vaccine - C-31-G - MucoCept Platform - HSV-2 Px - NVC-727 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - GV-2207 - MB-66 - Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - BA-368 - HSV-2 Vaccine - RKP-00156 - CEL-1000 - MAb hu2c - HSV Vaccine - Drug For Herpes Simplex Virus - Subunit Vaccine for Herpes Simplex Virus 2 - Small Molecules for Viral Infections - Small Molecules for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/2z...es_simplex
GENOCEA Co-Founder Receives TIME Magazine's TIME 100 Honor
Business Wire - Thu Apr 24, 7:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that TIME magazine has named company co-founder David A. Sinclair, Ph.D., to the 2014 TIME 100, its annual list of the 100 most influential people in the world. Recognized for his breakthroughs in aging research, Dr. Sinclair currently serves as a Professor of Genetics and co-Director of the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging at Harvard Medical School.
Genocea elects Jonathan Poole as CFO
M2 - Tue Apr 08, 6:04AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) disclosed on Monday that it has named Jonathan Poole as its chief financial officer.
Genocea Appoints Jonathan Poole as Chief Financial Officer
Business Wire - Mon Apr 07, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the appointment of Jonathan Poole to the position of chief financial officer. Mr. Poole joins Genocea from Shire plc (NASDAQ: SHPG).
Genocea to Present at the Needham & Company 13th Annual Healthcare Conference
Business Wire - Wed Apr 02, 8:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that its president and chief executive officer, Chip Clark, will present a company overview at the Needham & Company 13th Annual Healthcare Conference. The presentation is scheduled for Wednesday, April 9, 2014 at 10:40 a.m. ET at the Westin Grand Central Hotel in New York, NY.
Genocea Added to Russell 3000(R) and Russell 2000(R) Indices
Business Wire - Tue Apr 01, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it has been added to the Russell 3000(R) and Russell 2000(R) Indices as part of Russell Investments' first quarter 2014 IPO additions.
3 Biotech Stocks Rising on Unusual Volume
at The Street - Tue Apr 01, 5:00AM CDT
Keep these biotech stocks on your radar.
Genocea's Therapeutic Vaccine for Herpes Simplex-2 Infection Shows Highly Significant Reductions in Clinical Symptoms at 6 Months
Business Wire - Mon Mar 24, 2:00PM CDT
Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (Nasdaq: GNCA) for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose. Genocea, a company pioneering novel T cell vaccines and immunotherapies, reported the results from the ongoing trial of GEN-003 today as an oral presentation at the World Vaccine Congress, being held March 24-26 in Washington, DC.
Genocea Biosciences Announces Collaboration to Characterize T Cell Responses to Cancer Antigens
Business Wire - Mon Mar 03, 8:00AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a company pioneering novel T cell vaccines and immunotherapies, today announced a joint research collaboration with Dana-Farber Cancer Institute and Harvard Medical School to characterize anti-tumor T cell responses in melanoma patients. This collaboration extends the use of the company's proprietary ATLAS(TM) platform for the rapid discovery of T cell antigens to cancer immunotherapy approaches.
Genocea to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Tue Feb 25, 8:02AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell enabled vaccines and immunotherapies, announced today that its president and chief executive officer, Chip Clark, will present a company overview at the Cowen and Company 34th Annual Health Care Conference. The presentation is scheduled for Monday, March 3, 2014 at 4:10 p.m. EST at the Boston Marriott Copley Place.
Genocea Biosciences Inc concludes IPO at USD12.00 per share
M2 - Tue Feb 11, 6:37AM CST
T cell vaccines company Genocea Biosciences Inc (Nasdaq GM:GNCA)) reported on Monday the completion of its initial public offering of 5,500,000 shares of its common stock.
Genocea Biosciences, Inc. Announces Closing of Initial Public Offering
Business Wire - Mon Feb 10, 11:00AM CST
Genocea Biosciences, Inc. today announced the closing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $12.00 per share. After underwriting discounts and commissions and estimated offering expenses, Genocea received net proceeds of approximately $61.4 million, excluding estimated offering expenses. The shares are listed on the NASDAQ Global Market under the ticker symbol "GNCA."
Genocea Biosciences, Inc. Announces Pricing of Initial Public Offering
Business Wire - Wed Feb 05, 8:00AM CST
Genocea Biosciences, Inc. today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $12.00 per share, before underwriting discounts. In addition, Genocea has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the same price to cover over-allotments, if any. The shares are scheduled to begin trading on the NASDAQ Global Market on February 5, 2014 under the ticker symbol "GNCA."
Genocea Reports First Quarter 2014 Financial Results
Business Wire - Tue May 06, 7:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported its financial results for the first quarter ended March 31, 2014.
Genocea to Announce First Quarter 2014 Financial Results on May 6, 2014
Business Wire - Tue Apr 29, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on May 6, 2014 at 9:00 a.m. ET to discuss financial results for the quarter ended March 31, 2014. The presentation, hosted by Genocea president and chief executive officer Chip Clark and chief financial officer Jonathan Poole, will also provide an update on the company's recent progress and upcoming milestones.
Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles
M2 - Mon Apr 28, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zbrdd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Vical Incorporated - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Nutra Pharma Corporation - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - Spider Biotech S.r.l. - Kala Pharmaceuticals, Inc. - Coridon Pty Ltd - Sanofi Pasteur SA - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - amenamevir - tenofovir - RPI-78M - RPI-MN - HSV-2 Vaccine - CEL-1000 - HSV Vaccine - HSV-2 Vaccine - C-31-G - MucoCept Platform - HSV-2 Px - NVC-727 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - GV-2207 - MB-66 - Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - BA-368 - HSV-2 Vaccine - RKP-00156 - CEL-1000 - MAb hu2c - HSV Vaccine - Drug For Herpes Simplex Virus - Subunit Vaccine for Herpes Simplex Virus 2 - Small Molecules for Viral Infections - Small Molecules for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/2z...es_simplex
GENOCEA Co-Founder Receives TIME Magazine's TIME 100 Honor
Business Wire - Thu Apr 24, 7:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that TIME magazine has named company co-founder David A. Sinclair, Ph.D., to the 2014 TIME 100, its annual list of the 100 most influential people in the world. Recognized for his breakthroughs in aging research, Dr. Sinclair currently serves as a Professor of Genetics and co-Director of the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging at Harvard Medical School.
Genocea elects Jonathan Poole as CFO
M2 - Tue Apr 08, 6:04AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) disclosed on Monday that it has named Jonathan Poole as its chief financial officer.
Genocea Appoints Jonathan Poole as Chief Financial Officer
Business Wire - Mon Apr 07, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the appointment of Jonathan Poole to the position of chief financial officer. Mr. Poole joins Genocea from Shire plc (NASDAQ: SHPG).
Genocea to Present at the Needham & Company 13th Annual Healthcare Conference
Business Wire - Wed Apr 02, 8:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that its president and chief executive officer, Chip Clark, will present a company overview at the Needham & Company 13th Annual Healthcare Conference. The presentation is scheduled for Wednesday, April 9, 2014 at 10:40 a.m. ET at the Westin Grand Central Hotel in New York, NY.
Genocea Added to Russell 3000(R) and Russell 2000(R) Indices
Business Wire - Tue Apr 01, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it has been added to the Russell 3000(R) and Russell 2000(R) Indices as part of Russell Investments' first quarter 2014 IPO additions.
3 Biotech Stocks Rising on Unusual Volume
at The Street - Tue Apr 01, 5:00AM CDT
Keep these biotech stocks on your radar.
Genocea's Therapeutic Vaccine for Herpes Simplex-2 Infection Shows Highly Significant Reductions in Clinical Symptoms at 6 Months
Business Wire - Mon Mar 24, 2:00PM CDT
Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (Nasdaq: GNCA) for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose. Genocea, a company pioneering novel T cell vaccines and immunotherapies, reported the results from the ongoing trial of GEN-003 today as an oral presentation at the World Vaccine Congress, being held March 24-26 in Washington, DC.
Genocea Biosciences Announces Collaboration to Characterize T Cell Responses to Cancer Antigens
Business Wire - Mon Mar 03, 8:00AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a company pioneering novel T cell vaccines and immunotherapies, today announced a joint research collaboration with Dana-Farber Cancer Institute and Harvard Medical School to characterize anti-tumor T cell responses in melanoma patients. This collaboration extends the use of the company's proprietary ATLAS(TM) platform for the rapid discovery of T cell antigens to cancer immunotherapy approaches.
Genocea to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Tue Feb 25, 8:02AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell enabled vaccines and immunotherapies, announced today that its president and chief executive officer, Chip Clark, will present a company overview at the Cowen and Company 34th Annual Health Care Conference. The presentation is scheduled for Monday, March 3, 2014 at 4:10 p.m. EST at the Boston Marriott Copley Place.
Genocea Biosciences Inc concludes IPO at USD12.00 per share
M2 - Tue Feb 11, 6:37AM CST
T cell vaccines company Genocea Biosciences Inc (Nasdaq GM:GNCA)) reported on Monday the completion of its initial public offering of 5,500,000 shares of its common stock.
Genocea Biosciences, Inc. Announces Closing of Initial Public Offering
Business Wire - Mon Feb 10, 11:00AM CST
Genocea Biosciences, Inc. today announced the closing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $12.00 per share. After underwriting discounts and commissions and estimated offering expenses, Genocea received net proceeds of approximately $61.4 million, excluding estimated offering expenses. The shares are listed on the NASDAQ Global Market under the ticker symbol "GNCA."
Genocea Biosciences, Inc. Announces Pricing of Initial Public Offering
Business Wire - Wed Feb 05, 8:00AM CST
Genocea Biosciences, Inc. today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $12.00 per share, before underwriting discounts. In addition, Genocea has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the same price to cover over-allotments, if any. The shares are scheduled to begin trading on the NASDAQ Global Market on February 5, 2014 under the ticker symbol "GNCA."
